TW200738676A - Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists - Google Patents
Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonistsInfo
- Publication number
- TW200738676A TW200738676A TW095121918A TW95121918A TW200738676A TW 200738676 A TW200738676 A TW 200738676A TW 095121918 A TW095121918 A TW 095121918A TW 95121918 A TW95121918 A TW 95121918A TW 200738676 A TW200738676 A TW 200738676A
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- heteroaryl
- heterocycloalkyl
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69211005P | 2005-06-20 | 2005-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200738676A true TW200738676A (en) | 2007-10-16 |
Family
ID=36968725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095121918A TW200738676A (en) | 2005-06-20 | 2006-06-19 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
Country Status (17)
Country | Link |
---|---|
US (2) | US7635705B2 (zh) |
EP (1) | EP1902046B1 (zh) |
JP (1) | JP2008546784A (zh) |
KR (1) | KR20080021082A (zh) |
CN (1) | CN101243072A (zh) |
AR (1) | AR054787A1 (zh) |
AT (1) | ATE450526T1 (zh) |
AU (1) | AU2006262441A1 (zh) |
CA (1) | CA2610959A1 (zh) |
DE (1) | DE602006010870D1 (zh) |
ES (1) | ES2337727T3 (zh) |
HK (1) | HK1121737A1 (zh) |
IL (1) | IL187984A0 (zh) |
MX (1) | MX2008000115A (zh) |
TW (1) | TW200738676A (zh) |
WO (1) | WO2007001975A1 (zh) |
ZA (1) | ZA200710968B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
US20070142369A1 (en) * | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
EA200900539A1 (ru) * | 2006-10-20 | 2009-10-30 | Эрет Терэпьютикс, Инк. | Соединения фенилмочевины (варианты), содержащая их фармацевтическая композиция и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой (варианты) |
JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
JP2010516787A (ja) * | 2007-01-29 | 2010-05-20 | アレテ セラピューティクス, インコーポレイテッド | 代謝症候群および関連障害の処置のための可溶性エポキシドヒドロラーゼ阻害剤 |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
TW200840571A (en) * | 2007-03-02 | 2008-10-16 | Schering Corp | Piperidine derivatives and methods of use thereof |
EA200901240A1 (ru) * | 2007-03-13 | 2010-02-26 | Эрет Терэпьютикс, Инк. | Соединения 4-пиперидинилмочевины (варианты), фармацевтическая композиция на их основе (варианты) и способ лечения заболевания, опосредованного растворимой эпоксидгидролазой, посредством названных соединений (варианты) |
US8933101B2 (en) | 2007-04-23 | 2015-01-13 | Janssen Pharmaceutica Nv | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
SI2148873T1 (sl) | 2007-04-23 | 2013-01-31 | Janssen Pharmaceutica, N.V. | Derivati 4-alkoksipiridazina kot antagonisti receptorja dopamina 2 s hitro disociacijo |
JP2010527915A (ja) * | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ,インコーポレイテッド | 多重環化合物及びその用途 |
GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
US8530474B2 (en) | 2008-07-03 | 2013-09-10 | Janssen Pharmaceutica Nv | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists |
EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
CA2730774C (en) | 2008-07-31 | 2016-09-13 | Janssen Pharmaceutica Nv | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
EP2404902A1 (en) | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
US8337835B2 (en) * | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
KR101723707B1 (ko) * | 2010-01-22 | 2017-04-05 | 다이호야쿠힌고교 가부시키가이샤 | Pgds 저해 작용을 갖는 피페라진 화합물 |
NZ604035A (en) | 2010-06-04 | 2015-02-27 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
KR20140038361A (ko) * | 2011-01-07 | 2014-03-28 | 타가셉트 인코포레이티드 | 니코틴 수용체 비-경쟁적 길항제 |
US8865641B2 (en) * | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
WO2013040316A1 (en) | 2011-09-16 | 2013-03-21 | Galectin Therapeutics, Inc. | Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
CN102657868A (zh) * | 2012-05-30 | 2012-09-12 | 中国药科大学 | 5-羟色胺2受体拮抗剂或转运体抑制剂治疗脂肪肝或高脂血症 |
CN104619329B (zh) | 2012-06-06 | 2018-01-26 | 卡莱克汀医疗有限公司 | 用于治疗与升高的诱导型一氧化氮合酶相关联的疾病的半乳糖‑鼠李糖半乳糖醛酸酯组合物 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN109082465A (zh) * | 2018-08-20 | 2018-12-25 | 苏州市广济医院 | 奥氮平诱导糖代谢紊乱相关疾病的分子标志物及其用途 |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
WO2021187605A1 (ja) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | 含窒素複素環αシアノカルボニル化合物 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US661145A (en) * | 1900-08-06 | 1900-11-06 | Otto Hausmann | Attachment for bicycles. |
US856473A (en) * | 1906-05-21 | 1907-06-11 | Daniel E Krause | Drilling-machine. |
US4983567A (en) * | 1987-03-16 | 1991-01-08 | Biomeasure, Inc. | Immunomodulators and methods of making same |
US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5561227A (en) * | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
MY131273A (en) * | 1991-07-23 | 2007-07-31 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
ATE205475T1 (de) * | 1993-07-09 | 2001-09-15 | Schering Corp | Verfahren zur herstellung von azetidinonen |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
AU7472896A (en) | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
HUP9904362A3 (en) | 1996-08-16 | 2000-12-28 | Schering Corp | Treatment of upper airway allergic responses with a combination of histamine h1 and h3 receptor antagonists |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
US6133001A (en) * | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
JP2002518368A (ja) * | 1998-06-17 | 2002-06-25 | デュポン ファーマシューティカルズ カンパニー | メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類 |
US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
WO2000063703A1 (en) * | 1999-04-16 | 2000-10-26 | Schering Corporation | Use of azetidinone compounds |
CZ20022720A3 (cs) * | 2000-02-11 | 2002-11-13 | Vertex Pharmaceuticals Incorporated | Deriváty piperazinu a piperidinu pro pouľití při léčení a prevenci poąkozených neuronů |
US20020045686A1 (en) * | 2000-08-24 | 2002-04-18 | The Yokohama Rubber Co., Ltd | Rubber composition having improved wet skid resistance and rolling resistance |
DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
NZ526594A (en) * | 2000-12-21 | 2004-08-27 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
DE50111751D1 (de) * | 2000-12-21 | 2007-02-08 | Sanofi Aventis Deutschland | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
EP1373251A2 (en) | 2001-03-13 | 2004-01-02 | Schering Corporation | Non-imidazole compounds as histamine h3 antagonists |
ES2245733T3 (es) * | 2001-03-28 | 2006-01-16 | Schering Corporation | Sintesis enantioselectiva de compuestos intermedios de azetidinona. |
US20030137689A1 (en) * | 2002-01-18 | 2003-07-24 | General Instrument Corporation. | Remote printer driver server |
AR040406A1 (es) * | 2002-04-18 | 2005-04-06 | Schering Corp | Antagonistas de histamina h3 de benzimidazolona |
US7105505B2 (en) * | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
DK1499316T3 (da) * | 2002-04-18 | 2008-07-21 | Schering Corp | (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister |
DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DK1539742T3 (da) * | 2002-06-24 | 2006-12-27 | Schering Corp | Indolderivater, der er nyttige som histamin H3-antagonister |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
KR101095288B1 (ko) | 2002-08-06 | 2011-12-16 | 사노피-아벤티스 도이칠란트 게엠베하 | 장내 콜레스테롤 결합 단백질의 분리방법 |
US20040198743A1 (en) * | 2003-01-31 | 2004-10-07 | Schering Corporation | Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists |
CN100439361C (zh) * | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
EP1606287B1 (en) * | 2003-03-07 | 2013-10-02 | Merck Sharp & Dohme Corp. | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
EP1601669B1 (en) * | 2003-03-07 | 2008-12-24 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
JP2006528939A (ja) | 2003-04-23 | 2006-12-28 | グラクソ グループ リミテッド | ピペラジン誘導体ならびに神経および精神疾患の治療のためのその使用 |
US20040224952A1 (en) * | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
GB0315360D0 (en) | 2003-07-01 | 2003-08-06 | Burns Robert N | Anti-theft device |
AU2003259547A1 (en) | 2003-07-31 | 2005-02-14 | Hetero Drugs Limited | Ezetimibe polymorphs |
WO2005021495A2 (en) | 2003-08-25 | 2005-03-10 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
US20070161577A1 (en) | 2003-08-28 | 2007-07-12 | Martinez Eduardo J | Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones |
GB0321228D0 (en) | 2003-09-10 | 2003-10-08 | Inpharmatica Ltd | Modulating cell activity |
EP1677803A2 (en) | 2003-09-26 | 2006-07-12 | Forbes Medi-Tech Inc. | Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
EP1682117A1 (en) | 2003-10-30 | 2006-07-26 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
WO2005046662A2 (en) | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
DE602004008100T2 (de) | 2003-11-10 | 2008-04-30 | Microbia Inc., Cambridge | 4-biarylyl-1-phenylazetidin-2-one |
EP1699760B1 (en) | 2003-12-23 | 2017-05-17 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
DE602004029715D1 (de) | 2003-12-23 | 2010-12-02 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
-
2006
- 2006-06-19 US US11/455,625 patent/US7635705B2/en not_active Expired - Fee Related
- 2006-06-19 KR KR1020077030855A patent/KR20080021082A/ko not_active Application Discontinuation
- 2006-06-19 AT AT06773528T patent/ATE450526T1/de not_active IP Right Cessation
- 2006-06-19 JP JP2008518276A patent/JP2008546784A/ja not_active Withdrawn
- 2006-06-19 CA CA002610959A patent/CA2610959A1/en not_active Abandoned
- 2006-06-19 DE DE602006010870T patent/DE602006010870D1/de active Active
- 2006-06-19 ES ES06773528T patent/ES2337727T3/es active Active
- 2006-06-19 AU AU2006262441A patent/AU2006262441A1/en not_active Abandoned
- 2006-06-19 MX MX2008000115A patent/MX2008000115A/es active IP Right Grant
- 2006-06-19 TW TW095121918A patent/TW200738676A/zh unknown
- 2006-06-19 CN CNA2006800301178A patent/CN101243072A/zh active Pending
- 2006-06-19 EP EP06773528A patent/EP1902046B1/en active Active
- 2006-06-19 WO PCT/US2006/023800 patent/WO2007001975A1/en active Application Filing
- 2006-06-20 AR ARP060102617A patent/AR054787A1/es not_active Application Discontinuation
-
2007
- 2007-12-06 IL IL187984A patent/IL187984A0/en unknown
- 2007-12-18 ZA ZA200710968A patent/ZA200710968B/xx unknown
-
2008
- 2008-09-23 HK HK08110560.1A patent/HK1121737A1/xx not_active IP Right Cessation
-
2009
- 2009-07-22 US US12/507,563 patent/US7846946B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008546784A (ja) | 2008-12-25 |
HK1121737A1 (en) | 2009-04-30 |
EP1902046B1 (en) | 2009-12-02 |
ES2337727T3 (es) | 2010-04-28 |
DE602006010870D1 (de) | 2010-01-14 |
US20090286830A1 (en) | 2009-11-19 |
IL187984A0 (en) | 2008-03-20 |
CA2610959A1 (en) | 2007-01-04 |
MX2008000115A (es) | 2008-03-18 |
ZA200710968B (en) | 2009-03-25 |
AR054787A1 (es) | 2007-07-18 |
CN101243072A (zh) | 2008-08-13 |
WO2007001975A8 (en) | 2008-01-24 |
WO2007001975A1 (en) | 2007-01-04 |
EP1902046A1 (en) | 2008-03-26 |
US7635705B2 (en) | 2009-12-22 |
US7846946B2 (en) | 2010-12-07 |
KR20080021082A (ko) | 2008-03-06 |
ATE450526T1 (de) | 2009-12-15 |
US20070015807A1 (en) | 2007-01-18 |
AU2006262441A1 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200738676A (en) | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | |
HK1114850A1 (en) | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists | |
IL189069A0 (en) | Piperidine and piperazine derivatives as p2x3 antagonists | |
TW200628154A (en) | Organic compounds | |
ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
JP2010538076A5 (zh) | ||
WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
NO20062098L (no) | Faststofftilstandmontelukast | |
CA2536870A1 (en) | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists | |
AR064319A1 (es) | Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros | |
TW200621755A (en) | Oxime ester compound and photopolymerization initiator containing such compound | |
JP2007518682A5 (zh) | ||
ATE484502T1 (de) | Neue verbindungen | |
ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
ATE540675T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
BRPI0514415A (pt) | composto, composição farmacêutica, e, uso de um composto | |
CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
WO2008149834A1 (ja) | ピリミドジアゼピノン誘導体 | |
AR046310A1 (es) | Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas. | |
TW200621223A (en) | Acyclic 1,3-diamines and uses therefor | |
ATE399164T1 (de) | Antagonisten des opioidrezeptors | |
MX2011009700A (es) | Derivado de amida. | |
BRPI0918966A8 (pt) | composto inibidor de proteases, composição farmacêutica compreendendo dito compostos e uso terapêutico do mesmo |